Highest-materiality recent filing
Tandem Diabetes shareholders approve charter amendments and equity plan increase at annual meeting
Shareholders approved charter amendments to allow removal of directors with or without cause and limit officer liability per DGCL Sections 141(k) and 102(b)(7).
Tandem Diabetes terminates CCO Mark Novara without cause; last day May 18
Mark Novara, EVP & Chief Commercial Officer, notified of termination without cause on May 11, 2026.
Earnings release filed; exhibit not provided in context
Tandem Diabetes Care filed 8-K for Q1 2026 earnings.
Tandem Diabetes closes $300M zero-coupon convertible notes due 2032; net proceeds ~$290.7M
Issued $300M aggregate principal of 0.00% Convertible Senior Notes due 2032 (including $35M greenshoe exercised).
Tandem Diabetes issues Q4/FY2025 earnings release; specific results not provided in filing excerpt
Filing reports issuance of press release for quarter and year ended 12/31/2025.
Tandem Diabetes amends bylaws with updated advance notice, proxy card, voting rules
Board adopted Amended and Restated Bylaws on Dec 26, 2025 as part of periodic governance review.
Tandem Diabetes appoints Sandra Beaver to board, adds audit and cybersecurity roles
Sandra Beaver joined the board effective Nov. 7, 2025, increasing board size from 8 to 9.
Earnings press release for quarter ended September 30, 2025 was furnished as Exhibit 99.1.
Tandem Diabetes receives FDA 510(k) clearance for SteadiSet infusion set for 7-day use
FDA cleared SteadiSet infusion set for up to seven days of use; features integrated inserter with hidden needle.
Q2 2025 earnings release furnished; no specific figures provided in filing text
Press release dated June 30, 2025, furnished as Exhibit 99.1, but content not included in the provided filing text.
Tandem settles patent disputes with Roche, agrees to pay $36M over five years
Settlement resolves pending patent actions in France and Germany regarding t:slim X2 pump and two EP patents.
CE mark granted for Tandem Mobi insulin delivery system with Control-IQ+ technology.
FDA cleared SteadiSet infusion set for up to 3 days of use; submission by subsidiary CapBio.
Tandem Diabetes Care files Q1 2025 results; no financial details in filing excerpt
8-K filed April 30, 2025 announcing Q1 2025 financial results.
Tandem Diabetes Care releases Q4/FY2024 earnings; financial figures not provided in filing excerpt
Company issued press release on February 26, 2025 for Q4 and full year 2024 results.
Tandem Diabetes reports Q3 2024 results; no details in furnished text
Filing states a press release was issued for Q3 ended September 30, 2024.
Tandem Diabetes Care reports Q2 2024 results via press release (exhibit text not provided)
Filed 8-K indicating a press release was issued on Aug 1, 2024 for Q2 ended June 30, 2024.
Tandem Diabetes appoints Jean-Claude Kyrillos as EVP, COO effective June 21, 2024
Kyrillos previously served as President of Diagnostics & Digital Solutions at Envista Holdings and held senior roles at Qualcomm Life, BD, and ResMed.
Tandem and Dexcom amend agreements to integrate Sigi pump with G7 CGM for five years
On May 22, 2024, Tandem and Dexcom entered into two amended and restated agreements.
Tandem Diabetes stockholders approve 3M-share increases to ESPP and LTIP at annual meeting
Stockholders elected all 9 director nominees; highest vote count for John Sheridan (50.3M for).
Tandem obtains Health Canada approval for Trurapi U-100 compatibility with t:slim X2 pump
Health Canada approved adding Trurapi U-100 to compatible insulins list for t:slim X2 with Control-IQ in Canada.
Tandem Diabetes Care reports Q1 2024 results; specific figures not provided in filing text
Press release dated May 2, 2024 covers quarter ended March 31, 2024.
FDA clears Tandem Mobi insulin pump for pediatric use ages 2+
FDA cleared Tandem Mobi insulin pump for expanded pediatric indication in individuals two years and older.
Issued $316.25M aggregate principal amount of 1.50% Convertible Senior Notes due 2029, including full exercise of initial purchasers' option for additional $41.25M.
Tandem Diabetes reports Q4/FY2023 results; detailed metrics not available in filing text
Press release furnished as Exhibit 99.1 contains financial results for quarter and year ended Dec 31, 2023.
On May 11, 2026, Mark Novara, the Executive Vice President and Chief Commercial Officer of Tandem Diabetes Care, Inc. (the “Company”), was notified that his employment with the Company is being terminated without cause.
On June 19, 2024, the Board of Directors of Tandem Diabetes Care, Inc. (the “Company”) approved the appointment of Jean-Claude Kyrillos as Executive Vice President, Chief Operating Officer effective June 21, 2024.
Max materiality 0.80 · Median 0.50 · Most common event earnings